The effects of DSIP on pain threshold during light and dark periods in rats are not naloxone-sensitive.
Yehuda. S S; Carasso. R L RL
Key Findings
- 0.1 mg/kg DSIP increased pain threshold in both light and dark periods and shifted the peak tolerance from 10:00 to 18:00.
- 1.0 mg/kg DSIP raised pain threshold only during the dark (night) period.
- The analgesic effect of DSIP was not reversed by naloxone, indicating a non‑opioid mechanism.
Practical Outcomes
- DSIP shows promise as a non‑opioid pain‑modulating agent that can also alter circadian pain patterns in rats. However, the study is animal‑only, uses injectable dosing, and lacks human safety or efficacy data, so it isn’t ready for direct biohacker protocols. More research is needed before considering DSIP for pain or sleep‑related self‑experiments.
Summary
In rats, a low dose of the peptide DSIP raised the pain tolerance both during the day and night and moved the time when rats were most pain‑resistant from morning to evening. A higher dose only helped at night, and the pain‑relief effect wasn’t blocked by naloxone, meaning it doesn’t work through the usual opioid system.
Abstract
The effects of Delta-Sleep-Induced Peptide (DSIP) were examined in rats kept at 12:12 light:dark schedule. The peak of the circadian pain threshold of saline-treated rats occurred at 10:00. Rats treated with 0.1 mg/kg, i.p. DSIP exhibited a significantly higher pain threshold level (as measured by hot plate) both in the light and dark periods. Prior to the treatment the peak was at 10:00. With treatment the peak shifted to 18:00. A dose of 1.0 mg/kg DSIP increased the pain threshold level only during the dark period. The analgesia induced by DSIP is insensitive to naloxone pretreatment.
Study Information
pubmed
1987
10.3109/00207458708991805
4
9